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The progress in molecular and cell biology has enabled a rational exploitation of the natural resources
of the secondary metabolites and biomaterials from sponges (phylum Porifera). It could be established
that these natural substances are superior for biomedical application to those obtained by the traditional
combinatorial chemical approach. It is now established that the basic structural and functional elements
are highly conserved from sponges to the crown taxa within the Protostomia (Drosophila melanogaster
and Caenorhabditis elegans) and Deuterostomia (human); therefore, it is obvious that the molecular eti-
ology of diseases within the metazoan animals have a common basis. Hence, the major challenge for
scientists studying natural product chemistry is to elucidate the target(s) of a given secondary metabo-
lite, which is per se highly active and selective. After this step, the potential clinical application can be
approached. The potential value of some selected secondary metabolites, all obtained from sponges and
their associated microorganisms, is highlighted. Examples of compounds that are already in medical use
(inhibition of tumor/virus growth [arabinofuranosyl cytosine and arabinofuranosyl adenine]), or are
being considered as lead structures (acting as cytostatic and anti-inflammatory secondary metabolites
[avarol/avarone], causing induction of apoptosis [sorbicillactone]) or as prototypes for the interference
with metabolic pathways common in organisms ranging from sponges to humans (modulation of path-
ways activated by fungal components [aeroplysinin], inhibition of angiogenesis [2-methylthio-1,4-
napthoquinone], immune modulating activity [FK506]) are discussed in this study. In addition, bioactive
proteins from sponges are listed (antibacterial activity [pore-forming protein and tachylectin]). Finally,
it is outlined that the skeletal elements—the spicules—serve as blueprints for new biomaterials, espe-
cially those based on biosilica, which might be applied in biomedicine. These compounds and biomate-
rials have been isolated/studied by members of the German Center of Excellence BIOTECmarin. The
goal for the future is to successfully introduce some of these compounds in the treatment of human dis-
eases in order to raise the public awareness on the richness and diversity of natural products, which
should be sustainably exploited for human benefit.
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The first part of this review, Traditional and Modern Biomedical Prospecting:
Part I—the History. Sustainable Exploitation of Biodiversity (Sponges and
Invertebrates) in the Adriatic Sea in Rovinj (Croatia), by Werner EG Müller,
Renato Batel, Heinz C Schröder and Isabel M Müller appeared recently in
Evidence-based Complementary and Alternative Medicine 2004;1:71–82.Rationale
Until six years ago, it was assumed that the approaches of
combinatorial chemistry to identify compounds for biomedical
application, as drugs or biomaterials, might be the only prom-
ising route to identify lead structures for therapeutic use.
However, presently, bioprospecting of secondary metabolites
from marine sessile filter feeders appears superior to the chem-
ical approach. The change toward this paradigm is surely based
on the progress achieved in the identification and structure
analysis of natural compounds using methods such as the ana-
lytical hyphenation triad (HPLC-MS/MS-NMR-CD) intro-
duced by Bringmann (1). Another major progress attributed to
the renaissance of the natural products, especially those from
lower invertebrates, was achieved after the causal, analytic
screening, based on the achievements in molecular-chemical
ecology, proved to be successful (2,3). Particularly, the com-
prehensive understanding of the molecular biology of the
sponges, and to some extent, also that of other sessile filter
feeders, provided the impetus for this rational screening
approach. It could be demonstrated that (i) the gene repertoire
of the sponges (phylum Porifera) is highly diverse (4,5), and (ii)
the basic structural, metabolic and disease-related pathways in
these animals are closely related to those found in other meta-
zoans including humans (4). One example is the finding that the
sponge secondary metabolite, 2-methylthio-1,4-naptho-
quinone, causes an inhibition of canal formation in sponges as
well as of vessel formation in the chick chorioallantoic mem-
brane assay (6).
In view of these (unexpected) findings, an accelerated
progress in the identification of new lead compounds useful
for biomedical application can be expected. In recent and com-
prehensive reviews (7,8) a wide activity spectrum of secondary
metabolites has been highlighted. Moreover, it has become
increasingly obvious that the economical value of natural
products (secondary metabolites) for potential biomedical
application is by far higher than that of compounds obtained
by chemical synthesis. It has been estimated that among a
given number of 5000 to 10 000 chemically synthesized
compounds, only 10 reach clinical phase I, because it is only
at this step that the evidence of the concept can be assessed (9)
(Fig. 1). In contrast, the evidence of the concept of secondary
metabolites, i.e., whether a given compound actually com-
prises biological activity, has been provided for free by nature
(10). Only those secondary metabolites that are biologically
active could survive during the long evolutionary history; they
were even fortified with respect to selectivity and biological
activity in the subsequent rounds of evochemical selection.
Focusing on sponges, a conceptual progress occurred with
the study of Thakur (11), who suggested that these animals and
their symbiotic microorganisms (bacteria and fungi) produce
an array of bioactive compounds against foreign attackers. A
recent concept is the notion that symbiosis is driven by envi-
ronmental biotic constraints (Fig. 2). FIRST (DIRECT PROTEC-
TION): The host (sponge) synthesizes bioactive compounds that
provide protection against attacking microorganisms or
eukaryotes, e.g., acetylenic compounds (12). The symbiotic
bacteria or fungi produce secondary metabolites that act as
antibiotics, e.g., cribrostatin (13), or as cytostatic agents, e.g.,
sorbicillactone A (14). Functionally, these compounds act
(most probably) only as defense molecules. SECOND (DIRECT
PROTECTION): Another functional class of secondary metabol-
ites of sponges and their associated microorganisms play a
dual role; they are involved in defense as well as in the activa-
tion of pathways crucial for self-defense (metabolic activator).
The first proven example is that of okadaic acid. We could
demonstrate that okadaic acid is produced in the sponge
Suberites domuncula by bacteria; it acts firstly as a defense
molecule against foreign metazoan attackers and simultane-
ously by a positive modulation of those pathways, which aug-
ment the immune response of the host (15). THIRD (IMMUNE
PROTECTION): The sponge produces proteinaceous bioactive
molecules that arrest the growth of bacteria, e.g., perforin (11)
and tachylectin (16), or that destroy eukaryotic cells, e.g.,
agglutinins (17). FOURTH (INDIRECT PROTECTION): If required,
the sponge host harbors selected bacterial strains on its surface
that produce bioactive compounds acting specifically against
fouling bacteria (11), e.g., tribromophenol (18).
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Figure 1. High value of (natural) secondary metabolites in compar-
ison with compounds obtained by combinatorial chemistry. Left:
The number of chemicals synthesized solely in a combinatorial
chemical manner, which have potential biomedical value, decreases
drastically during the preclinical and clinical screening/testing
phases. If at all, very few compounds reach the stage of registration
(9). Right: Natural secondary metabolites are per se biologically
active. If the biological target of a given compound could be
identified, (ideally) all of them can reach the clinical phases.It must be stressed that recently, virus-related genes have
also been identified in S. domuncula, indicating that sponges
may also be infected by viruses. This conclusion is not
surprising considering the fact that the virus load of the water
filtrated by the sponges is considerably high; up to 108 virus
particles per ml have been determined in aquatic environments
(19,20).
Selected Bioactive Compounds from Marine
Sponges and Associated Microorganisms:
Low Molecular Weight Compounds
Providing a comprehensive overview of the secondary metabol-
ites that have been isolated until now from sponges and their
associated microorganisms is outside the scope of this review;
during 1998 to 1999, more than 2000 original studies have
been published (8), and bioactive compounds are reviewed
regularly (7,21,22). In this paper, we focus on those com-
pounds which were discovered by members of the German
Center of Excellence ‘BIOTECmarin’.
This consortium has selected the Adriatic Sea, in the vicinity
of Rovinj (Croatia), as its field station. This area is character-
ized by a high abundance of species, especially with respect to
sponges—approximately 200 species have been described.
Furthermore, in accordance with the tradition of this Institute
(Center of Marine Research) since 1891, the laboratory is well
equipped, and the infrastructure is highly competent (10). It is
very interesting that this northern Adriatic region changed into
a marine environment only after the post-pleistocenic rise of the
sea level. This transgression occurred only 10 000 years ago.
Five kilometers north of Rovinj, the unique underwater
biotope—the ‘Limski Canal’(a fjord-like bay)—protrudes into
the interior of the peninsula. Presently, this canal is 11 km long.
Old maps such as the one from Ortelius (1580), depict the canal
as being connected with a 20 km long river (Lemo fl. in Fig. 3
[left]). This ‘river Draga’does not carry water any more; it is a
dry valley. This geological change, the drying up of the river
feeding the Limski Canal, caused dramatic effects on the
human population, e.g., on villages such as Dvigrad that were
abandoned (in the year 1631). In addition, it most certainly
affected the marine biotic populations in the Limski Canal. This
tectonic, and consequently also ecological, change might be
one of the reasons why this biotope and the organisms in the
Limski Canal are considerably different from those in the open
sea (23). Perhaps, this difference is also an evolutionary cause
for the development of endemic species described in the Limski
Canal, e.g., the sponges Tethya limski (24), Geodia rovinjensis
(25) and Thoosa istriaca (26).
These unique local conditions resulted in the protection of
the Limski Canal as a distinguished marine protected area
devoted to evo-devo studies.
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Figure 2. Strategies of sponges, together with their symbiotic microorganisms, bacteria and fungi, for protection against attackers. Sponges are provided with
two forms of direct protections; (i) single protection and (ii) dual protection. In single protection, bioactive molecules are produced which are directed only toward
the invading pro- and eukaryotic organisms. In the dual form of protection, the secondary metabolites are directed against the non-self organisms and also posi-
tively modulate the host metabolism. (iii) The sponges produce defense proteins that neutralize/kill foreign prokaryotic pathogenic microorganisms and eukary-
otic predators (immune protection). (iv) The sponges facultatively comprise surface bacteria that produce antifouling secondary metabolites (indirect protection).
The red arrows indicate bacterial origin, and the blue ones indicate that the compounds are produced by sponges. Examples of secondary metabolites and proteins
involved in these strategies of protection are provided.Inhibition of Tumor/Virus Growth:Arabinofuranosyl
Cytosine-Arabinofuranosyl Adenine
To date, only two compounds, 1- -D-arabinofuranosyl cytosine
and 1- -D-arabinofuranosyl adenine, that had been modified
from a secondary metabolite isolated from a sponge,
Cryptotethya crypta, are in clinical use (27). Species related to
this taxon are Tethya lyncurium and Tethya limski,w h i c h  a r e
found in the Rovinj area (Fig. 4Ac and Ad). T. lyncurium is also
the sponge species about which the oldest descriptions (28,29)
are available (Fig. 4Aa and Ab). 1- -D-arabinofuranosides of
thymine and uracil were isolated and used as ‘blueprints’for the
development of drugs to treat cancer (1- -D-arabinofuranosyl
cytosine [ara-C]) or herpes simplex virus infection (1- -D-
arabinofuranosyl adenine [ara-A]) (Fig. 4B).
Arabinofuranosyl cytosine: The usefulness of ara-C as a
potential anticancer drug can be traced back to Cohen (30).
As summarized in this review, ara-C potently inhibits the
growth of leukemia cells in vitro and in vivo, and is still very
frequently used in human cancer chemotherapy. It was discov-
ered that it acts by inhibiting the DNA synthesis in leukemic
cells (31). Moreover, it was demonstrated that the nucleoside
analog can even be incorporated into the DNA, a finding that
might explain the teratogenic and mutagenic potential of
this drug. In parallel, it was demonstrated that ara-C is
intracellularly phosphorylated to ara-CTP, a nucleotide that
acts as a strong competitive inhibitor for mammalian DNA
polymerases (32).
Arabinofuranosyl adenine: A further boost to the arabino-
furanosyl nucleosides as therapeutically important drugs was
provided by the studies on ara-A. After having identified and
isolated the herpes simplex virus (HSV) coded DNA
polymerase (33), it was possible to demonstrate that this
viral enzyme is strongly and competitively inhibited by the
triphosphate derivative of ara-A (34) (Fig. 4C). The degree of
inhibition can be quantitated by calculating the ratio between
the Km value (Michaelis constant) and the Ki value (inhibitor
constant). The Km:Ki values in the assays with dATP and ara-
ATP for the cellular polymerases (  and  ) as well as the Rous
sarcoma virus DNA polymerase are low (in the range of 1 to
2). However, HSV DNA polymerase is inhibited with a ratio
close to 100, indicating the high degree of selectivity of this
nucleoside analog. Based on this and subsequent studies, ara-
A was introduced worldwide for anti-HSV treatment as
Vidarabin (Germany), Vira-A (USA), Vidarabine (China),
Arasena-A (Japan) or Vira-MP (France). In Japan, ara-A is the
most frequently applied ointment against herpes simplex virus
infection (Arasena-A® [Mochida Pharmaceutical Co, Tokyo]).
The major reason for this success was the fact that the bioac-
tive compound ara-A can be synthesized in unlimited amounts.
Cytostatic and Anti-inflammatory Secondary
Metabolite:Avarol/Avarone
After the discovery that isoprene (2-methylbutadiene) is the
building block of terpenes (35), it was found 30 years ago that
isoprenoids are among the most diverse secondary metabolites
in sponges (36). Perhaps, the most extensively studied
sesquiterpenoid is the hydroquinone avarol and its quinone
avarone. These secondary metabolites were isolated from the
sponge Dysidea avara by Minale (37) and De Rosa (38). Its
biological activity as a cytostatic/anti-leukemic compound was
described (39) and its anti-HIV activity (human immunodefi-
ciency virus type 1) was also established (40). The latter result
was confirmed by several studies (41,42). Finally, it was estab-
lished that the compound displays anti-inflammatory activity
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Figure 3. Research area around Rovinj (Croatia). Left: A map of Ortelius (year 1580 [Histriae tabula a Petro Coppo]) depicting the Limski Canal (arrow) with
the connected river Lemo flumen. It has its source in the 20 km distant mountains. Right:A map from 1900 (67), showing the 11 km long Limski Canal. Similarly,
another river (Arsa flumen) (arrow head), which had been connected with the lake Vrana in the year 1580, disappeared later. In the Limski Canal, endemic sponge
species, e.g., Tethya limski, Geodia rovinjensis and Thoosa istriaca have been described. The scale bar is provided close to the location of Rovinj.(43). Clinical trials were initiated; but had to be stopped
primarily due to the shortage of starting material.
Based on the awareness that secondary metabolites from
sponges have a chance to be applied for human benefit in a
wider sense only if a sustainable exploitation is guaranteed,
intense efforts have been undertaken to produce these secondary
metabolites in a bioreactor. With the establishment of the prim-
morph system, it became—although not yet in a satisfactory
manner—likely that sponge metabolites can be produced by cell
culture in vitro (44).
Modulation by Fungal Components:Aeroplysinin
From the Mediterranean sponge Verongia (Aplysina)
aerophoba (Fig. 5), the brominated metabolite—aeroplysinin
(Fig. 5)—was isolated (45), which displays antibacterial (45)
and anti-tumor activity (46). Interestingly, aeroplysinin acts as
an anti-angiogenic compound in the chick embryo system
(47). Cell biological studies with the sponge confirmed that the
compound is synthesized by the sponge itself and not by
symbiotically associated bacteria (48).
As originally shown in the mammalian system (49), aero-
plysinin was also recently demonstrated to cause inhibition of
tyrosine kinase in the sponge S. domuncula (3). Relevant to the
understanding of how the sponges detect potential parasitic or
symbiotic microorganisms was the finding that S. domuncula
contains a cell surface receptor, which recognizes (1→ 3)- -D-
glucan, a carbohydrate indicative of fungi. The expression of the
(1→ 3)- -D-glucan binding protein receptor could be blocked
by aeroplysinin. Further, the genes coding for the downstream
proteins in the signal response circuit, the fibrinogen-like pro-
tein and the epidermal growth factor (EGF)-precursor proteins
were modulated in response to aeroplysinin treatment (Fig. 5).
It could be concluded that the (1→ 3)- -D-glucan-recognizing
receptor controls, after binding of the ligand, the expression of
a protein involved in the recognition of fungi (fibrinogen), and
of a cytokine that modulates cell proliferation (EGF) (Fig. 5).
Induction of Apoptosis: Sorbicillactone A
As outlined earlier, sponges have developed strategies to defend
themselves against foreign organisms—prokaryotic, eukaryotic
or viral attackers—by the production of secondary metabolites
that repel them (21,50). It is known that some potent anti-
microbial compounds, especially antibiotics, are produced by
microorganisms such as bacteria (e.g., Streptomyces) and fungi
(‘Fungi imperfecti’, e.g., Penicillium). Consequently, and tele-
ologically speaking, sponges have utilized the capability of
these microorganisms as symbionts to enhance their potency to
synthesize bioactive compounds.
Several efforts have been undertaken to cultivate the sym-
bionts—in this case, fungi—that are associated with sponges. In
the course of this research, different fungal strains were isolated
from Mediterranean sponges and tested for bioactivity. Among
the activities, the novel compound sorbicillactone A (Fig. 6B),
which was recently isolated at the Center of Excellence
‘BIOTECmarin’ from a strain of fungus Penicillium chryso-
genum (14), was characterized (Fig. 6A). P. chrysogenum was
obtained from a sample of the Mediterranean sponge Ircinia
fasciculata; sorbicillactone A possesses a unique bicyclic lactone
structure, which appears to be derived from sorbicillin. Among
the numerous known sorbicillin-derived structures, it is the
first to contain nitrogen and thus, the first representative of a
novel type of ‘sorbicillin alkaloids’. This compound exhibits
promising activities in several mammalian and viral test
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Figure 4. Arabinofuranosyl cytosine. (A) Sponges of the genus Tethya
(Demospongiae)—views from the past and the present. (Aa) a sketch of this
sponge by Gesner (1558); (Ab) a picture of Tetia sphaerica (Donati 1753);
(Ac) Tethya lyncurium or Tethya aurantium with its protruding buds [ 3];
(Ad)  Tethya limski, an endemic species from the ‘Limski Canal’ (Rovinj;
Croatia) [ 0.5]. (B) Evolutionary shaping (evochemistry) of a normal
metabolite (adenosine) into a bioactive secondary metabolite (ara-A) in the
sponge Cryptotethya crypta during over 500 million years of biochemical
selection for the highest potency in action and selectivity in function. (C)
Mode of action of ara-A. This nucleoside analog in its triphosphorylated form
competitively inhibits the herpes simplex virus (HSV) coded DNA poly-
merase. The ratio of the Michaelis constant (Km) and the inhibitor constant
(Ki) reflects the efficacy of this inhibitor on HSV polymerase.systems. It is highly selective in its cytostatic activity against
murine leukemic lymphoblasts (L5178y) (Fig. 6C).
Recently, it was also established that the mode of action of sor-
bicillactone A is through the induction of apoptosis in leukemic
cells. This finding, together with the selective inhibition of tumor
cells, may qualify sorbicillactone A (or one of its derivatives) for
animal and (hopefully) also future therapeutic human trials. The
potential applicability is further supported by our success in
upscaling the production of this natural product from amounts
less than a milligram to a scale above 50 g; this method could
be developed in only 3 months and was directed by Profs G
Bringmann (Würzburg) and JF Imhoff (Kiel) at the Center of
Excellence. Crystals of sorbicillactone A are shown in Fig. 6D.
Interestingly, sorbicillactone A displays no effect on sponge
cells, as tested with S. domuncula.
Inhibition of Angiogenesis: 2-methylthio-1,4-
napthoquinone
Molecular biological studies have provided compelling
evidence that sponges share basic receptor/ligand systems,
especially those involved in body plan formation and in
immune recognition, with the higher metazoan phyla. An estab-
lished in vitro cell/organ-like culture system from sponges, the
primmorphs, comprises proliferating and differentiating cells,
but not the typical canals of the aquiferous system.
Recently, we succeeded in transferring the primmorphs from
the demosponge S. domuncula to a homologous matrix
(galectin), in order to induce the formation of canal-like struc-
tures in these 3D-cell aggregates. In parallel with the forma-
tion of the canals, a gene is expressed whose deduced protein
falls into the CD36/LIMPII receptor family. We cloned the
receptor and found that it is strongly expressed after adhesion
of primmorphs to the galectin matrix. This process could be
suppressed if primmorphs were co-incubated with a homolo-
gous polypeptide containing the CSVTCG domain, that was
until recently found only in thrombospondin-1 (and related)
molecules of vertebrates. In situ hybridization studies revealed
that the S. domuncula CD36/LIMPII receptor is localized in
the pinacocytes, the cells that surround the canals in sponges.
Furthermore, a secondary metabolite, 2-methylthio-1,4-
napthoquinone (MTN), was isolated and characterized from a
sponge-associated bacterium. MTN causes inhibition of cell
proliferation of vertebrate tumor cells at concentrations
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Figure 5. Aeroplysinin. The Mediterranean sponge Verongia aerophoba (left) produces the secondary metabolite aeroplysinin (right). This tyrosine kinase
inhibitor modulates the recognition system of sponges for fungi. The fungal model compound curdlan, composed of (1→ 3)-b-D-glucan, interacts with its recep-
tor, the (1→ 3)- -D-glucan binding protein (GLUBP), in the S. domuncula system. Controlled by a tyrosine kinase, which can be inhibited by the aeroplysinin,
this recognition results in an expression of three genes: one coding for the glucan binding protein precursor (GLUBPp), the second for the fibrinogen-like protein
(FIBG) and the third for the epidermal growth factor (EGF)-precursor. While fibrinogen is assumed to be involved in the recognition of fungi, EGF might be
involved in the control of proliferation of sponge cells.of  80 ng/ml. However, only doses of 2 mg/ml are required to
potently inhibit angiogenesis in the chick chorioallantoic
membrane assay. This compound was also found to suppress
the expression of the S. domuncula CD36/LIMPII at concen-
trations of 10 ng/ml; this result is the first indication that this
secondary metabolite comprises a conserved functional activ-
ity, the suppression of the formation of the circulation system,
from sponges to vertebrates (6).
Immune Modulating Activity: FK506
Another bioactive compound that causes the same biologi-
cal/therapeutic effect in sponges and also in humans is worth
mentioning. The background in this case is that molecular and
functional data indicate that sponges possess molecules simi-
lar to and homologous with those of the innate and adaptive
immune systems of higher metazoa (51).
Applying the biological system of parabiosis and the tech-
nique of differential display of mRNA, two sponge cDNAs
encoding putative FK506-binding proteins have been isolated.
This finding was interesting, since FK506 is successfully
applied in clinics as a drug to prevent allograft rejection. This
secondary metabolite was found to be toxic to S. domuncula
cells in vitro at doses above 100 ng/ml. Autograft fusion of
transplants from S. domuncula was not affected by FK506.
Allograft non-fusion was not affected by FK506 at toxic doses;
however, at the non-toxic dose of 20 ng/ml, the allografts fused
with each other. It has been demonstrated that at the attachment
zone in untreated (especially drastic) and in FK506-treated
allografts, the expression of the genes encoding the FK506-
binding proteins is upregulated. These data indicate that the
drug FK506 suppresses allograft rejection in S. domuncula
most probably via interaction with the expression of the gene
coding for the FK506-binding proteins (52).
On the basis of these data, we propose that sponges possess
the key pathways for the disease control observed in mammals
and present day species, and respond to drugs successfully
used to treat disorders in higher mammals.
Bacterial Gene Cluster
Sponges are (always) associated with bacteria; most of them
are known to produce polyketides, e.g., swinholide produced
by the lithistid sponge Theonella swinhoei (53), a class of com-
pounds that display highly potent (especially) antibiotic activi-
ties. However, most of the bacteria present in sponges are
considered to be non-culturable. To exploit the bioactive poten-
tial of these microorganisms, molecular biotechnological tech-
niques must be developed. One promising approach is to clone
the polyketide synthases, which synthesize the core of the
bioactive compound, and to express them in a heterologous
system. In the course of this attempt, polyketide synthases have
been isolated from the bacteria of the sponge S. domuncula
(54); the length is approximately 40 kb. The polyketide syn-
thases are multienzyme complexes that use simple organic
building blocks, e.g., acetyl-CoA and their derivatives. As
represented schematically in Fig. 7B, the polyketide synthases
comprise at least the following enzymic activities:  -keto
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Figure 6. Sorbicillactone A. (A) This secondary metabolite is synthesized by the sponge-associated fungus, Biconiosporella corniculata Schaumann
(Ascomycota). (B) Structure of sorbicillactone A. (C) Inhibitory activity of 0.4  g/ml of sorbicillactone A on murine leukemic lymphoblasts L5178y (leukaemia),
human cervix HeLa S3 cells (sarcoma) and rat adrenal phaeochromocytoma cells PC-12 (adenoma). The inhibitory activity of the compound on the respective
tumor cell lines is given in percentage. In parallel, the inhibition of sorbicillactone A was tested against S. domuncula cells, which remained almost non-affected.
(D) Crystals of sorbicillactone A, after having upscaled the production of this natural product to amounts in grams (courtesy Dr G Bringmann, Würzburg).acylthioester synthase, acyltransferase and acyl carrier protein
domain (55). In addition, other enzymic activities may be
included, e.g., ketoacyl-reductase, dehydratase, enoyl reductase
and thioesterase domains. Multiple copies of active site units
reminiscent of those of the fatty acid synthases exist.
Since almost all marine demosponges contain bacteria, the
benefit of such an association needs to be investigated. First,
data are now available that provide an insight into the molecu-
lar mechanism by which the host (sponge) might discriminate
between symbiotic or commensalic and parasitic bacteria.
Some of these symbiotic bacteria produce secondary metab-
olites. It is worth mentioning the recently obtained data as an
example of the biochemical basis of a symbiotic relationship
between bacteria and the sponge host. It could be demon-
strated that under optimal aeration conditions, S. domuncula
expresses the enzyme tyrosinase, which synthesizes diphenols
from monophenolic compounds (56). A cell surface ‘non-
culturable’bacteria (SB2) can be detected simultaneously with
this increased expression. The SB2 bacteria are known to
produce bioactive compound(s). The protocatechuate gene
cluster was cloned and sequenced from this SB2 bacterium.
This cluster comprises all genes coding for enzymes involved
in the conversion of protocatechuate to acyl-CoA. The expres-
sion is strongly induced if the bacteria are cultivated on
M9/protocatechuate medium. We concluded that metabolites,
in this case, diphenols, produced by the sponge S. domuncula,
are utilized by the sponge surface-associated bacterium for
energy generation. This approach will help further to uncover
the symbiotic pathways between sponges and their associated
‘non-culturable’ microorganisms (Fig. 7A).
Selected Bioactive Compounds:
Bioactive Proteins
Until recently, no conclusive data were available to ascertain
which bacterial strains are symbiotic and which are parasitic.
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Figure 7. Sponge-bacteria relationship. (A) Formation of diphenols
from monophenols mediated by the sponge enzyme tyrosinase. The
reaction product(s) is taken up by surface-associated bacteria and
used as carbon source. (B) Schematic model of the domains encoding
the polyketide synthase (KS) cloned from a bacterium that had been
isolated from the sponge S. domuncula (the scales indicate the
stretches on the DNA [given in kb]). Lower scheme: the modular
polyketide synthase is composed of at least the following enzymic
activities:  -keto acylthioester synthase (KS), acyltransferase (AT),
ketoacyl-reductase (KR), dehydratase (DH), enoyl reductase (ER)
and thioesterase domain (TE). Multiple copies of active site units
(in this case, KS-1 to KS-4) are usually present. The photograph at the
center of the figure shows a semi-thin section through the mesohyl
compartment adjacent to the lacunae, which are surrounded by an
epithelium (formed by endopinacocytes). One bacteriocyte (arrow
head) is shown, which is embedded in the epithelium that surrounds
a water canal (C); it is almost completely filled with bacteria (light
micrograph; [  250]).  Upper scheme: upstream of the polyketide
synthase cluster of this sponge-associated bacterium, genes encoding
for enzymes of the protocatechuate/ -ketoadipate pathway have been
identified (abbreviated as pcaB-pcaQ). This pathway uses benzoate
or p-hydroxybenzoate and forms succinyl-CoA and acetyl-CoA in the
cascade, metabolites that also enter the polyketide synthase cycle.
This pathway is used by the sponge-associated bacteria to utilize the
carbon source.Experimental data are now available to gain a preliminary
understanding of the molecular mechanism by which the host
(sponge) might discriminate between symbiotic or commen-
salic and parasitic bacteria. Certain bacterial strains can be
engulfed by specific sponge cells, the bacteriocytes (57), and
protein synthesis in tissue from S. domuncula is inhibited after
incubation with the bacterial endotoxin lipopolysaccharide
(LPS) (57).
An effective mechanism to eliminate microbes is intracellu-
lar digestion. This cellular defense mechanism against foreign
invaders is well developed in organisms ranging from sponges
to insects and humans. Sponges possess specialized amoeboid
cells, the archaeocytes, which have in the past been regarded
as the macrophages of sponges. Molecules involved in cellular
and humoral immunity have been isolated and functionally
analyzed in S. domuncula (4). Some molecules that are
toxic for pro- and eukaryotic non-self organisms are
mentioned here.
Antibacterial Activity: Pore-forming Protein
A cDNA clone was isolated from S. domuncula that resembles
human perforin; it displayed antibacterial activity (11). Human
perforin is found in lytic granules of cytotoxic natural killer
and T cells. After release, perforin forms pores in the target
cell membranes, initiating osmotic lysis. Hence, perforin is an
effector molecule of the non-specific cytotoxic T lymphocyte-
mediated defense system of mammalians. The recombinant
perforin protein from S. domuncula was prepared and found to
display antimicrobial activity. In an earlier study on the sponge
Tethya lyncurium, a pore-forming protein had been described,
which resembles other pore-forming toxins in size, e.g., the
E. coli hemolysin (17).
Antibacterial Activity: Tachylectin 
(a S. domuncula Lectin)
Another bioactive protein from a sponge worth mentioning
here is tachylectin (16). Recently, we have demonstrated the
existence of a tachylectin-related protein in S. domuncula,
which we termed Suberites lectin (tachylectin). In response to
lipopolysaccharide (LPS) treatment of primmorphs,the mitogen-
activated protein kinase pathway is activated; this process is
abolished by the monosaccharide N-acetyl-D-glucosamine 
(D-GlcNAc). The cDNA encoding the S. domuncula lectin was
identified and cloned. The steady state level of expression of
the Suberites lectin rises in primmorphs in response to LPS,
an effect that was prevented by co-incubation with D-GlcNAc.
We purified the natural sponge lectin by affinity chromatogra-
phy; it has a size of 27 kDa and displays antibacterial activity
against the gram-negative Escherichia coli and the gram-
positive Staphylococcus aureus. The putative protein, deduced
from the cloned gene, was identical/similar to the natural pro-
tein, as demonstrated by immunological cross-reactivity with
specific antibodies. We conclude that the S. domuncula lectin
acts as an antibacterial molecule involved in immune defense
against bacterial invaders.
Unique Biomaterials in Sponges: Silica
Among the metazoan phyla, primarily sponges, more specific-
ally the Demospongiae and Hexactinellida, contain a skeleton
that is composed of hydrated, amorphous and non-crystalline
silica. This inorganic material is deposited in the spicules, their
major skeletal elements (58) (Fig. 8). In 1859 (59), the first
publication on sponges, the freshwater sponge Spongilla fluvi-
atilis appeared as a model in which detailed analyses on the
development and differentiation of fertilized eggs were pro-
vided. Even the differentiation stages of the sponge cells, e.g.,
from the ‘Schwärmsporen’ to the spicule-forming sclerocytes
were described in detail (Fig. 8Aa). Similarly, a few years
later, DeLage (60) precisely observed that the spicules are
formed intracellularly (Fig. 8 Ab). It is notable that he men-
tioned that the spicule-containing cell ‘est de même nature que
les amoeboïdes’. This remark can also be considered as an
indication that he had been aware of the new concept of stem
cells that originated at this time (61).
In the past few years, silicate metabolism in sponges has
been elucidated to some extent (62). The formation of the
spicules is a rapid process; in the freshwater sponge Ephydatia
fluviatilis, the 100–300  m long spicules are synthesized
under optimal conditions within 40 h. The rate of appearance
of the new spicules is correlated with the growth of the oscu-
lar tube, implying that an efficient relocation system must be
active in order to place the spicules at their functional destina-
tion. In addition, reorganization and disorganization processes
in sponges, such as the bud formation, require an efficient
machinery to replace spicules. The shape and growth forms
of the spicules are incredibly multiform and fascinating. In
this paper, samples from the glass sponge (Hexactinellida)
Hyalonema sieboldi are presented. The 300 mm long basal
spicules (Fig. 8B) are compactly bundled and intricately
twisted. On this basal tuft, the sponge body is placed, which
appears as a raised hide. Scanning electron microscopy reveals
that the large basal spicules are built by concentric layers of
silica. These layers are characterized by glass of varying
refractive indices (Fig. 8Ba and b). Owing to this unique
structure, the spicules can transmit light through their silica
skeleton (Fig. 8C).
Needless to mention, biosilica has a wide range of applica-
tions in the medical field, from novel biomaterials for bone
replacements to the stabilization of the tissue.
Anabolic Enzyme for the Synthesis of Silica: Silicatein
The enzyme silicatein from Demospongiae has been
described, and it polymerizes silicon alkoxide substrates to sil-
ica (62,63). It could be demonstrated in the primmorph system
from  S. domuncula that spicule formation is genetically
controlled. In primmorphs, silicon-responsive genes, e.g.,
silicatein, collagen and myotrophin, are upregulated if the
primmorphs are grown at 60  M silicate. A pathway could
be proposed by which the spicules are formed in sclerocytes
in concert with the expression of myotrophin and collagen in
lophocytes and/or spongocytes. Furthermore, it was reported
eCAM 2004;1(2) 141that the size of primmorphs drastically increased if they were
cultivated in iron-containing medium, indicating that Fe3  ions
are required for the proliferation of cells in primmorphs from
S. domuncula. In parallel, Fe3  induces the expression of fer-
ritin and potently stimulates the synthesis of spicules. This
result is supported by the finding that the enzymic activity of
silicatein—converting organosilicon to polymerized silicic
acid—depends on Fe3 . Moreover, the expression of a scav-
enger receptor molecule, possibly involved in the morphology
of spicules, depends on the presence of Fe3 . We conclude that
iron is an essential factor in proliferative and morphogenetic
processes in primmorphs of sponges.
Catabolic Enzyme: Silicase
In the course of further elucidating the metabolism of
siliceous spicules in Demospongiae, another enzyme, silicase,
was identified from the marine sponge S. domuncula; silicase
can depolymerize amorphous silica. Using the ‘differential
display’ technique of transcripts, one cDNA was identified
that encodes a carbonic anhydrase-like enzyme, the silicase.
The deduced polypeptide is 379 aa long and is very similar to
the family of carbonic anhydrases. The recombinant silicase
was prepared; besides a carbonic anhydrase activity, it
displays the ability to dissolve amorphous silica under the
formation of free silicic acid. To support the results from the
‘differential display’, Northern blot studies were performed.
They revealed that after incubation of cells/tissue from 
S. domuncula, the expressions of the genes encoding the
catabolic enzyme silicase as well as the anabolic enzyme
silicatein increased (64).
Biomedical Potential
The need for silica as a starting source for biomedical applica-
tions is huge and ranges from the coating of artificial bones to
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Figure 8. Spicules from siliceous sponges. (A) (Aa) Differentiation of embryonic ‘Schwärmsporen’into differentiated spicule-forming sclerocytes (in Spongilla
fluviatilis) (59). (Ab) The intracellular formation of the spicules was also precisely observed by DeLage (60). (B) Scanning electron microscopic analysis of basal
spicules (Ba: cross section; Bb: side view) from Hyalonema sieboldi showing the concentric silica layers that constitute them. (C) Use of one basal spicule from
H. sieboldi as a light conductor. A laser beam is directed at one end of a spicule through which the light is transmitted to the other end.the implants of xenogeneic and allogeneic tissues. The find-
ings that the spicules of sponges are both enzymatically syn-
thesized (using the enzyme silicatein) and enzymatically
degraded (using the enzyme silicase) hints at applications in
biotechnology that are yet to be quantified, ranging from the
potential use of silicon-based materials in optics and electron-
ics to biomedicine.
Equally promising are the results obtained with the calcare-
ous skeleton from corals. It comprises a similar suitable
matrix. For example, the use of coral granules in alveolar ridge
preservation first stabilizes the bone defects and is subse-
quently replaced (65). In a straightforward study implementing
modern molecular biological and cell biological techniques, it
could be demonstrated that if coral samples are combined with
recombinant human bone morphogenetic protein-2 (rhBMP-
2), the new matrix thus obtained can substitute bone in the
field of orthopedics and maxillofacial surgery (66).
The Future (Evochemistry) and Conclusion
In the past, combinatory chemistry resulted in the synthesis
of numerous compounds. The availability of high numbers
of synthetic compounds demanded efficient high throughput
screening methods and processes, which have now become
available. In parallel with this development and the need for
novel lead structures for new pharmacologically active drugs,
there was a great demand for a multitude of extracts from nat-
ural sources, including sponges. However, this rationale is not
justified since the ‘quality’of the extracts from natural sources
is often fundamentally distinguished from a (merely stochastic-
ally synthesized) chemical product. It should be realized that
the bioactive compounds, which are synthesized in nature to
protect a particular organism, had been selected from a wide
variety of possibilities that allowed the intermediary meta-
bolism, and were under the pressure of evolution for several
hundreds of million years to reach optimal activity.
The consequences of a changed view and appreciation of
extracts from natural sources are that—in contrast to the
approach with chemicals produced by combinatory chem-
istry—natural extracts should not be primarily tested in a wide
variety of test batteries; rather, they should be tested in a
rational manner with the help offered by the biological
systems from which the compounds have been extracted.
Owing to the progress initiated by the pressure of the society
for sustainable use of natural resources for human benefit, the
exploitation of natural biodiversity became possible through
the application of the techniques of molecular biology and
modern cell biology.
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